HCAT

In the past six months, Health Catalyst's stock price increased by 48.7% to $1.76 per share, despite reaching an all-time low of $0.96 on April 9, 2026. The company reported Q2 CY2026 revenue of $70.49 million, exceeding market expectations but representing a 12.7% year-on-year decline, with non-GAAP profit of $0.04 per share meeting consensus. Following these results, the company's revenue guidance for the next quarter was $55.5 million, 10.7% below analysts' estimates, and full-year revenue guidance was lowered by 5.7% to $247.5 million at the midpoint. Other significant events include the appointment of Simeon Kohl as CEO and the divestiture of Vitalware.